Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.31)
# 4,144
Out of 4,876 analysts
38
Total ratings
15.62%
Success rate
-27.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $34.63 | +58.82% | 3 | May 14, 2025 | |
| VERV Verve Therapeutics | Upgrades: Overweight | n/a | $11.30 | - | 4 | Apr 15, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $16.80 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $65.35 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $9.56 | +579.92% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.26 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $2.28 | +514.04% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $47.49 | +125.31% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $34.63
Upside: +58.82%
Verve Therapeutics
Apr 15, 2025
Upgrades: Overweight
Price Target: n/a
Current: $11.30
Upside: -
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.80
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $65.35
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $9.56
Upside: +579.92%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.28
Upside: +514.04%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $47.49
Upside: +125.31%